Ainos, Inc. (AIMD)
- Previous Close
1.0600 - Open
1.0500 - Bid --
- Ask --
- Day's Range
1.0301 - 1.0899 - 52 Week Range
0.7900 - 6.1000 - Volume
37,357 - Avg. Volume
1,419,881 - Market Cap (intraday)
6.513M - Beta (5Y Monthly) 1.48
- PE Ratio (TTM)
-- - EPS (TTM)
-3.3600 - Earnings Date Aug 9, 2024 - Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
www.ainos.comRecent News: AIMD
Performance Overview: AIMD
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AIMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AIMD
Valuation Measures
Market Cap
6.51M
Enterprise Value
10.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
35.57
Price/Book (mrq)
0.27
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.42%
Return on Equity (ttm)
-46.62%
Revenue (ttm)
122.11k
Net Income Avi to Common (ttm)
-13.77M
Diluted EPS (ttm)
-3.3600
Balance Sheet and Cash Flow
Total Cash (mrq)
1.89M
Total Debt/Equity (mrq)
23.29%
Levered Free Cash Flow (ttm)
948.64k
Research Analysis: AIMD
Company Insights: AIMD
AIMD does not have Company Insights